Skip to Main content Skip to Navigation
Journal articles

Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro

Abstract : Pasireotide is a somatostatin analog (SSA) that targets somatostatin receptor subtype 1 (SST1), SST2, SST3, and SST5 with a high affinity. Pasireotide has a better antisecretory effect in acromegaly, Cushing's disease, and neuroendocrine tumors than octreotide. In this study, we compared the effects of pasireotide to those of octreotide in vitro on meningioma primary cell cultures, both alone and in combination with the mTOR inhibitor everolimus. Significant mRNA expression levels of SST1, SST2, and SST5 were observed in 40.5%, 100%, and 35% of meningioma samples, respectively. Pasireotide had a significantly stronger inhibitory effect on cell proliferation than octreotide. The effect of pasireotide, but not of octreotide, was significantly stronger in the group expressing the highest level of SST1 mRNA. Combined treatment with pasireotide and everolimus induced a higher reduction in cell viability than that with octreotide plus everolimus. Moreover, pasireotide decreased Akt phosphorylation and reversed everolimus-induced Akt hyperphosphorylation to a higher degree than octreotide. Using 4E-BP1 siRNA (si4E-BP), we demonstrated that 4E-BP1 protein silencing significantly reversed the response to everolimus, both alone and in combination with SSAs. Moreover, si4E-BP completely reversed the inhibition of cyclin D1 expression level and the increase in p27kip1 induced by SSAs, both alone and in combination with everolimus. Our results strongly support the need for further studies on the combination of pasireotide and everolimus in medical therapy for meningiomas.
Document type :
Journal articles
Complete list of metadatas

https://hal-amu.archives-ouvertes.fr/hal-01731578
Contributor : Anne Barlier <>
Submitted on : Tuesday, April 10, 2018 - 12:43:56 PM
Last modification on : Wednesday, August 19, 2020 - 12:08:20 PM

File

2017-Graillon-Oncotarget.pdf
Publisher files allowed on an open archive

Identifiers

  • HAL Id : hal-01731578, version 1

Collections

Citation

Thomas Graillon, David Romano, Céline Defilles, Christophe Lisbonis, Alexandru Saveanu, et al.. Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro. Oncotarget, Impact journals, 2017, 8, pp.55361 - 55373. ⟨hal-01731578⟩

Share

Metrics

Record views

163

Files downloads

227